Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Berraondo

Showing results (1-10 of 187) with videos related to

Pageof 19
Sort By:
Hemasphere|March 21, 2022
Mechanisms of action for different checkpoint inhibitorsPedro Berraondo
The Journal of Experimental Medicine|November 4, 2020
4-1BB (CD137) in anticancer chimerasIgnacio Melero, Pedro Berraondo
Frontiers in Immunology|March 5, 2016
Immunological Landscape and Clinical Management of Rectal CancerElísabeth Pérez-Ruiz, Pedro Berraondo
Gut|January 9, 2024
Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinomaMarina Barcena-Varela, Pedro Berraondo
Immunotherapy|December 18, 2012
How can chemoimmunotherapy best be used for the treatment of colon cancer?José Medina-Echeverz, Pedro Berraondo
Oncoimmunology|June 22, 2012
Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatinRuben Hernandez-Alcoceba, Pedro Berraondo
Oncoimmunology|June 22, 2012
Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cellsJosé Medina-Echeverz, Pedro Berraondo
Annals of Translational Medicine|November 9, 2017
New trends in antitumor vaccines in melanomaMarcos Vasquez, Shirley Tenesaca, Pedro Berraondo
Immunity|March 17, 2016
Cancer Immunosurveillance Caught in the ActPedro Berraondo, Alvaro Teijeira, Ignacio Melero
Nature Biomedical Engineering|December 10, 2025
Trispecific engager overcomes tumoural immunosuppressive environmentFernando Aranda, Aline Risson, Pedro Berraondo
Pageof 19

Showing results (1-10 of 187) with videos related to

Sort By:
Pageof 19
Hemasphere|March 21, 2022
Mechanisms of action for different checkpoint inhibitorsPedro Berraondo
The Journal of Experimental Medicine|November 4, 2020
4-1BB (CD137) in anticancer chimerasIgnacio Melero, Pedro Berraondo
Frontiers in Immunology|March 5, 2016
Immunological Landscape and Clinical Management of Rectal CancerElísabeth Pérez-Ruiz, Pedro Berraondo
Gut|January 9, 2024
Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinomaMarina Barcena-Varela, Pedro Berraondo
Immunotherapy|December 18, 2012
How can chemoimmunotherapy best be used for the treatment of colon cancer?José Medina-Echeverz, Pedro Berraondo
Oncoimmunology|June 22, 2012
Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatinRuben Hernandez-Alcoceba, Pedro Berraondo
Oncoimmunology|June 22, 2012
Colon cancer eradication after chemoimmunotherapy is associated with intratumoral emergence of proinflammatory myeloid cellsJosé Medina-Echeverz, Pedro Berraondo
Annals of Translational Medicine|November 9, 2017
New trends in antitumor vaccines in melanomaMarcos Vasquez, Shirley Tenesaca, Pedro Berraondo
Immunity|March 17, 2016
Cancer Immunosurveillance Caught in the ActPedro Berraondo, Alvaro Teijeira, Ignacio Melero
Nature Biomedical Engineering|December 10, 2025
Trispecific engager overcomes tumoural immunosuppressive environmentFernando Aranda, Aline Risson, Pedro Berraondo
Pageof 19